Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Lantern Pharma Inc. is a clinical-stage biotechnology company focused on the discovery and development of precision oncology therapies. The company operates at the intersection of oncology drug development and artificial intelligence–driven data science, using computational biology to identify cancer patient populations most likely to respond to specific drug candidates. Lantern Pharma’s core strategy centers on improving clinical trial success rates and reducing development timelines through data-informed patient selection.
Founded in 2013, the company evolved from a traditional oncology development model into a technology-enabled precision medicine platform following the creation of its proprietary AI and machine-learning system. Lantern Pharma is publicly traded on the Nasdaq under the ticker LTRN and, as a clinical-stage company, does not generate commercial product revenue. Its value proposition is based on advancing a focused pipeline of oncology assets while leveraging data-driven insights as a strategic differentiator.
Business Operations
Lantern Pharma’s operations are organized around a single integrated business model encompassing oncology drug development and AI-enabled biomarker discovery. The company’s proprietary platform, RADR® (Response Algorithm for Drug Repositioning), aggregates genomic, transcriptomic, and clinical data to guide candidate selection, trial design, and patient stratification. Revenue generation is currently limited to non-recurring sources such as collaboration-related income, with the primary use of capital directed toward research and development.
The company’s pipeline includes multiple oncology candidates targeting genetically defined cancer subtypes, with programs spanning solid tumors and hematologic malignancies. Operations are primarily based in the United States, with clinical trials conducted through third-party research organizations and academic partners. Lantern Pharma relies on external manufacturers, contract research organizations, and clinical investigators rather than owning large-scale laboratory or manufacturing assets.
Strategic Position & Investments
Strategically, Lantern Pharma positions itself as a precision oncology platform company, emphasizing capital efficiency and targeted development rather than broad therapeutic expansion. Its growth strategy prioritizes advancing late preclinical and clinical-stage assets in indications where molecular signals suggest higher probability of success, while selectively expanding the RADR® platform’s data depth and predictive capabilities.
Key pipeline programs include LP-300, an oncology candidate evaluated in genetically defined subsets of non-small cell lung cancer, and LP-184, a DNA-damage–targeting agent designed for tumors with specific DNA repair deficiencies. The company has also advanced LP-100, a program focused on hematologic malignancies, though public disclosures indicate varying levels of clinical maturity across assets. Lantern Pharma has not disclosed material acquisitions; instead, it emphasizes internal development and strategic research collaborations. Data inconclusive based on available public sources regarding any material equity investments or joint venture holdings.
Geographic Footprint
Lantern Pharma is headquartered in Dallas, Texas, and its corporate and strategic management functions are primarily based in the United States. The company’s operational footprint is asset-light, with clinical development activities conducted across multiple regions through international trial sites and research partners.
While Lantern Pharma does not maintain significant physical operations outside the U.S., its clinical programs and data assets reflect a global scope, incorporating patient data and trial participation from North America, Europe, and other international markets. This global reach supports the company’s precision medicine approach by increasing genetic and clinical diversity within its datasets.
Leadership & Governance
Lantern Pharma was founded by Panna Sharma, who continues to serve as President and Chief Executive Officer. The leadership team combines experience in oncology drug development, clinical research, and data-driven healthcare innovation. The company emphasizes a disciplined, data-centric leadership philosophy focused on improving development efficiency and aligning capital deployment with measurable clinical outcomes.
Key executives include:
- Panna Sharma – President and Chief Executive Officer
- Dr. Steven G. Best – Chief Medical Officer
- Kristin Peterson – Chief Financial Officer
The board of directors and executive leadership oversee corporate governance, strategic planning, and capital allocation, with an emphasis on regulatory compliance, shareholder alignment, and scientific rigor.